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Abstract: Protein tyrosine phosphatase 1B (PTP1B) plays a key role as a negative regulator in insulin
signal transduction by deactivating the insulin receptor. Thus, PTP1B inhibition has emerged as a
potential therapeutic strategy for curing insulin resistance. In this study, 40 extracts from 18 different
plant species were investigated for PTP1B inhibitory activity in vitro. The most promising one, the
EtOAc extract of Ficus racemosa, was investigated by high-resolution PTP1B inhibition profiling
combined with HPLC-HRMS-SPE-NMR analysis. This led to the identification of isoderrone (1),
derrone (2), alpinumisoflavone (3) and mucusisoflavone B (4) as PTP1B inhibitors. IC50 of these
compounds were 22.7 ± 1.7, 12.6 ± 1.6, 21.2 ± 3.8 and 2.5 ± 0.2 µM, respectively. Kinetics analysis
revealed that these compounds inhibited PTP1B non-competitively with Ki values of 21.3 ± 2.8,
7.9 ± 1.9, 14.3 ± 2.0, and 3.0 ± 0.5 µM, respectively. These findings support the important role of
F. racemosa as a novel source of new drugs and/or as a herbal remedy for treatment of type 2 diabetes.
Keywords: type 2 diabetes; PTP1B; Vietnamese medicinal plants; Ficus racemosa; isoflavonoids
1. Introduction
Diabetes mellitus has become a major and growing public health problem worldwide, affecting
415 million people and causing 5 million deaths in 2015. The number of people with diagnosed
diabetes is expected to increase by 55% between 2015 and 2040 to reach 642 million people, with the
majority of cases in low- and middle-income countries [1]. Type 2 diabetes (T2D), also known as
noninsulin-dependent diabetes, is the predominant form and causes more than 90% of all diabetes
cases [2]. The insulin resistance observed in T2D patients is caused by the inability of the cells
to propagate the insulin signal [3]. This results in postprandial hyperglycemia, causing severe
long-term complications, such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy and
cardiovascular diseases [4–6]. The insulin-signaling pathway is one of the key pathways responsible for
blood glucose regulation. When binding to its receptor, insulin triggers the autophosphorylation of the
insulin receptor and insulin receptor substrates (IRS). This activates several signaling cascades, leading
to biological responses such as glucose uptake into the cell and glycogen synthesis. Protein-tyrosine
phosphatase 1B (PTP1B) is an intracellular enzyme found in insulin-targeted tissues such as liver,
muscle, and fat. Acting as a negative regulator in the insulin-signaling pathway, PTP1B can
dephosphorylate, and thereby, deactivate the insulin receptor. Inhibition of PTP1B can reduce the
resistant state. This has been validated in a PTP1B knockout mice experiment, where insulin sensitivity
was enhanced in muscle and liver. On a high-fat diet, these mice were also resistant to weight gain
and remained insulin sensitive [7]. Therefore, PTP1B has become a promising therapeutic target for
the treatment of type 2 diabetes [7–9]. A large number of PTP1B inhibitors discovered from both
Molecules 2017, 22, 1228; doi:10.3390/molecules22071228 www.mdpi.com/journal/molecules
Molecules 2017, 22, 1228 2 of 12
natural and synthetic origin have been developed and investigated for their ability to stimulate insulin
signaling. However, none of them are approved for clinical use due to the poor cell permeability and
low bioavailability, which limit their potential as effective drugs [10].
For many years, natural products have been considered a valuable source of effective
antihyperglycemic phytochemicals. Several prenylated flavonoids, coumarins, terpenoids and related
compounds with affinity towards PTP1B have been identified [11]. Due to the chemical complexity of
plant extracts, identification of bioactive compounds as well as their isolation and structure elucidation
are obviously a difficult and time-consuming task. Simultaneously, minor components with interesting
bioactivity may be missed because their concentrations are below the detection threshold of the
biological screening or masked by other compounds in the complex mixture. In this study, we
therefore used high-resolution inhibition profiling, in which 96-well microfractionation of eluate from
analytical-scale high-performance liquid chromatography is followed by bioassaying of the material in
each well. This provides a high-resolution inhibition profile that can be overlaid with the corresponding
HPLC chromatogram to allow direct pinpointing of HPLC peaks correlated with bioactivity. These
peaks were subsequently analyzed using hyphenated high-performance liquid chromatography,
high-resolution mass spectrometry, solid-phase extraction, and nuclear magnetic resonance, i.e.,
HPLC-HRMS-SPE-NMR, which allows targeted isolation and structural characterization of bioactive
compounds directly from crude extract. The combined HR-bioassay/HPLC-HRMS-SPE-NMR platform
has been successfully applied for identification of bioactive constituents from natural sources such
as plant and food extract [12–17]. Here, we report crude extract screening of 40 Vietnamese plant
extracts (from 18 different plant species used for the treatment of type 2 diabetes) for PTP1B inhibitors,
followed by high-resolution PTP1B inhibition profiling in combination with HPLC-HRMS-SPE-NMR
analysis for identification of bioactive constituents.
2. Results and Discussion
2.1. PTP1B Inhibitory Activity of Crude Extracts
A total of 40 extracts from 18 different plant species (Table 1) were investigated. The EtOAc and
n-BuOH extracts were tested for their ability to inhibit PTP1B at a concentration of 100 µg/mL, and
extracts showing more than 80% inhibition (Figure 1) were considered to be active.
       
 
insulin signaling. However, none of them are approved for clinical use due to the poor cell 
permeability and low bioavailability, which limit their potential as effective drugs [10]. 
For many years, natural products have been considered a valuable source of effective 
antihyperglycemic phytochemicals. Several prenylated flavonoids, coumarins, terpenoids and 
related compounds with affinity towards PTP1B have been identified [11]. Due to the chemical 
complexity of plant extracts, identification of bioactive compounds as well as their isolation and 
structure elucidation are obviously a difficult and time-consuming task. Simultaneously, minor 
components with interesting bioactivity may be missed because their concentrations are below the 
detection threshold of the biological screening or masked by other compounds in the complex 
mixture. In this study, we therefore used high-resolution inhibition profiling, in which 96-well 
microfractionation of eluate from analytical-scale high-performance liquid chromatography is 
followed by bioassaying of the material in each well. This provides a high-resolution inhibition 
profile that can be overlaid with the corresponding HPLC chromatogram to allow direct pinpointing 
of HPLC peaks correlated with bioactivity. These peaks were subsequently analyzed using 
hyphenated high-performance liquid chromatography, high-resolution mass spectrometry, solid-
phase extraction, and nuclear magnetic resonance, i.e., HPLC-HRMS-SPE-NMR, which allows 
targeted isolation and structural characterization of bioactive compounds directly from crude extract. 
The combined HR-bioassay/HPLC-HRMS-SPE-NMR platform has been successfully applied for 
identification of bioactive constituents from natural sources such as plant and food extract [12–17]. 
Here, we report crude extract screening of 40 Vietnamese plant extracts (from 18 different plant 
species used for the treatment of type 2 diabetes) for PTP1B inhibitors, followed by high-resolution 
PTP1B inhibition profiling in combination with HPLC-HRMS-SPE-NMR analysis for identification 
of bioactive constituents. 
2. Results and Discussion 
2.1. PTP1B Inhibitory Activity of Crude Extracts 
A total of 40 extracts from 18 different plant species (Table 1) were investigated. The EtOAc and 
n-BuOH extracts were tested for their ability to inhibit PTP1B at a concentration of 100 µg/mL, and 
extracts showing more than 80% inhibition (Figure 1) were considered to be active.  
 
Figure 1. Protein tyrosine phosphatase 1B (PTP1B) inhibitory activity of EtOAc and n-BuOH extracts 
of 18 different plant species, at a concentration of 100 µg/mL, represented as mean ± standard 
deviation, n = 3. 
Thus, the EtOAc extracts of N. mirabilis, L. octovalvis, P. amarus, P. urinaria, C. fistula, S. cumini, E. 
hirta, R. mucronata, K. candel, P. odoratissimu, F. racemosa, and P. dulce, and the n-BuOH extracts of N. 
mirabilis, L. octovalvis, P. urinaria, L. speciosa, E. hirta, R. mucronata, K. candel, P. odoratissimus, and F. 
racemosa were selected for IC50 value determination. Crude extracts were dissolved in DMSO to obtain 
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s, t Et c extracts of N. mirabilis, L. octovalvis, P. amarus, P. urinaria, C. fistula, S. cumini,
E. hirta, R. mucronata, K. candel, P. odoratissimu, F. racemosa, and P. dulce, and the n-BuOH extracts of
N. mirabilis, L. octo alvis, P. urinaria, L. speciosa, E. hirta, R. mucronata, K. candel, P. doratissimus, and
Molecules 2017, 22, 1228 3 of 12
F. racemosa were selected for IC50 value determination. Crude extracts were dissolved in DMSO
to obtain a stock concentration of 10 mg/mL and serial ten-fold dilutions were performed six
times. Results showed that all these extracts strongly inhibited PTP1B with IC50 values ranging
from 0.02 to 74.4 µg/mL (IC50 of RK682 = 3.8 ± 0.6 µg/mL). The IC50 values of active extracts were
calculated from the dose-response curves (Supplementary data, Figures S1 and S2) and summarized in
Table 1. Previously, PTP1B inhibitory activity has been reported for a MeOH extract of P. reticulatus
(IC50 = 4.5 µg/mL [18]) and an EtOH extract of F. racemosa (IC50 = 12.1 µg/mL [19]). Besides this,
EtOAc and MeOH extracts of S. cumini have been reported as strong PTP1B inhibitors (IC50 = 1.9 ± 0.1
and 38.2 ± 0.1 µg/mL, respectively [20,21]). From the EtOAc extract, jamunones A–H, jamunones J–K,
jamunones M–O and spiralisone C were revealed as potent PTP1B inhibitors with IC50 values ranging
from 0.42 to 3.2 µM.
Table 1. IC50 values (µg/mL) of extracts showing more than 80% PTP1B inhibitory activity at a
concentration of 100 µg/mL.
IC50 (µg/mL)
Scientific Name Family Part Used Voucher No. EtOAc Extract n-BuOH Extract
Nepenthes mirabilis (Lour.) Druce Nepenthaceae Whole plant VN-01 1.4 ± 0.05 0.4 ± 0.1
Ludwigia octovalvis (Jacq.) P.H.
Raven Onagraceae Aerial part VN-02 16.9 ± 3.2 3.3 ± 0.3
Phyllanthus amarus Schumach. &
Thonn. Phyllanthaceae Whole plant VN-03 74.4 ± 3.9 n.t.
Phyllanthus urinaria L. Phyllanthaceae Whole plant VN-04 14.0 ± 0.8 10.8 ± 0.9
Phyllanthus reticulatus Poir. Phyllanthaceae Stem, leaf VN-05 n.t. n.t.
Scoparia dulcis L. Scrophulariaceae Whole plant VN-06 n.t. n.t.
Mirabilis jalapa L. Nyctaginaceae Root VN-07 n.t. n.t.
Arial part n.t. n.t.
Cassia fistula L. Leguminosae Leaf VN-08 24.1 ± 8.4 n.t.
Lagerstroemia speciosa (L.) Pers. Lythraceae Leaf VN-09 n.t. 19.6 ± 5.1
Syzygium cumini (L.) Skeels Myrtaceae Fruit VN-10 27.5 ± 7.8 n.t.
Euphorbia hirta L. Euphorbiaceae Whole plant VN-11 29.2 ± 6.2 38.3 ± 1.9
Rhizophora mucronata Lam. Rhizophoraceae Bark VN-12 17.2 ± 1.2 1.8 ± 0.4
Kandelia candel (L.) Druce Rhizophoraceae Bark VN-14 12.9 ± 2.2 0.02 ± 0.01
Cardiospermum halicacabum L. Sapindaceae Whole plant VN-14 n.t. n.t.
Pandanus odoratissimus L.f. Pandanaceae Fruit VN-15 20.8 ± 5.6 40.4 ± 7.9
Morinda citrifolia L. Rubiaceae Fruit VN-16 n.t. n.t.
Ficus racemosa L. Moraceae Fruit VN-17 38.3 ± 10.6 3.6 ± 1.4
Pithecellobium dulce (Roxb.) Benth. Leguminosae Stem VN-18 26.1 ± 2.5 n.t.
Leaf n.t. n.t.
n.t.: IC50 not tested because inhibition was less than 80% at 100 µg/mL. Values are expressed as mean ± standard
deviation (n = 3).
2.2. High-Resolution PTP1B Inhibition Profiles
All the active extracts were subjected to an analytical-scale HPLC (10 µL of 30 mg/mL extract),
using separation condition as described in Section 3.4. The chromatograms showed that most extracts
contained large amounts of tannins based on the large hump from 7 to 22 min (Supplementary data,
Figures S3 and S4). Tannins are polyphenolic compounds widely distributed in many plant species, and
are generally considered as non-specific inhibitors, which have low priority for drug discovery. Based
on the HPLC chromatograms, only EtOAc extracts of P. amarus, C. fistula, S. cumini, E. hirta, F. racemosa
and n-BuOH extracts of L. speciosa and F. racemosa had low levels of tannins. Chromatographic
separation of these extracts was thus optimized (described in Section 3.5) before being subjected to a
time-based microfractionation in 96-well microplates, followed by evaporation of the HPLC eluates
and assessment of the PTP1B inhibitory activity of all wells. The inhibitory activities (calculated as
percentage inhibition) were plotted against the retention time from the microfractionation to give the
high-resolution PTP1B inhibition profile (biochromatogram). The HPLC chromatogram at 254 nm is
shown with the black line and the high-resolution PTP1B inhibition profile shown with the red bars
(each bar represents inhibition of eluates in a well). The high-resolution PTP1B inhibition profiles of
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EtOAc extracts of P. amarus, C. fistula, S. cumini, and E. hirta and n-BuOH extracts of L. speciosa and
F. racemosa (Supplementary data, Figure S5) showed no distinct peaks with PTP1B inhibition despite
the significant inhibitory activities in the crude extracts. This can be caused by loss of synergistic
activities of constituents that are separated by microfractionation, but assessed collectively by the crude
extract screening. Therefore, no further investigation of these extracts was performed. An inhibition
region was observed from 27 to 34 min in the biochromatogram of F. racemosa EtOAc extract which
correlated to highly UV-absorbing signals (Figure 2). Because the biochromatogram could not pinpoint
clearly the active compounds, the F. racemosa EtOAc extract was subjected to preparative-scale HPLC
to obtain a fraction containing these signals (namely Fr.1, 12 mg) for further analysis.
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On the basis of HRMS as well as 1D NMR spectra obtained from HPLC-HRMS-SPE-NMR analysis,
peaks 1, 2 and 4 were assigned to isoderrone (1), C20H16O5, HR-ESIMS(+) m/z 337.1083 [M + H]+,
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1H-NMR (600 MHz, acetonitrile-d3) ppm: δ 12.91 (1H, s, OH-5), 8.02 (1H, s, H-2), 7.29 (1H, dd, J = 8.3,
2.2 Hz, H-6′), 7.22 (1H, d, J = 2.2 Hz, H-2′), 6.79 (1H, d, J = 8.3 Hz, H-5′), 6.42 (1H, d, J = 9.8 Hz, H-4′ ′),
6.40 (1H, d, J = 2.2 Hz, H-8), 6.27 (1H, d, J = 2.2 Hz, H-6), 5.75 (1H, d, J = 9.8 Hz, H-3′ ′), 1.42 (6H, s,
H3-5′ ′, H3-6′ ′) [22]; derrone (2), C20H16O5, HR-ESIMS(+) m/z 337.1074 [M + H]+, 1H-NMR (600 MHz,
acetonitrile-d3) ppm: δ 13.02 (1H, s, OH-5), 8.07 (1H, s, H-2), 7.40 (2H, d, J = 8.6 Hz, H-2′, H-6′), 6.89
(2H, d, J = 8.6 Hz, H-3′, H-5′), 6.72 (1H, d, J = 10.0 Hz, H-4′ ′), 6.22 (1H, s, H-6), 5.71 (1H, d, J = 10.0 Hz,
H-3′ ′), 1.46 (6H, s, H3-5′ ′, H3-6′ ′) [23]; alpinumisoflavone (3), C20H16O5, HR-ESIMS(+) m/z 337.1073
[M + H]+, 1H-NMR (600 MHz, acetonitrile-d3) ppm: δ 13.33 (1H, s, OH-5), 8.01 (1H, s, H-2), 7.39 (2H, d,
J = 8.6 Hz, H-2′, H-6′), 6.88 (2H, d, J = 8.6 Hz, H-3′, H-5′), 6.68 (1H, d, J = 10.0 Hz, H-4′ ′), 6.37 (1H, s,
H-8), 5.74 (1H, d, J = 10.0 Hz, H-3′ ′), 1.45 (6H, s, H3-5′ ′, H3-6′ ′) [24]. The structures of compound 1, 2, 3
are shown in Figure 4. The low content of the metabolites in the extract did not allow the trapping of
peaks 3, 5, 6 and 7 with a quantity and purity sufficient for NMR experiments.
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Figure 4. Structures of compounds 1–4 isolated from EtOAc extract of Ficus racemosa.
2.4. Isolation and Evaluation of Bioactive Compounds
From 40.0 g dried material of F. racemosa, 450 mg EtOAc extract was obtained and subsequently
subjected to preparative-scale HPLC (described in Section 3.6) to obtain the material eluted as peak 1
(3.5 mg), 2 (1.2 mg), 3 (0.7 mg), 4 (1.5 mg), 5 (1.2 mg), 6 (0.6 mg), and 7 (0.4 mg). On the basis of
HRMS as well as 1D and 2D NMR spectra, peak 5 was assigned to mucusisoflavone B (4), C40H32O10,
HR-ESIMS(+) m/z 673.2068 [M + H]+, 1H-NMR (600 MHz, acetone-d6) ppm: δ 13.03 (2H, s, OH-5,
OH-16′ ′), 8.24 (1H, s, H-13′ ′), 8.14 (1H, s, H-2), 7.74 (1H, d, J = 2.1 Hz, H-23′ ′), 7.37 (1H, dd, J = 8.3,
2.1 Hz, H-27′ ′), 7.35 (1H, dd, J = 8.2, 2.0 Hz, H-6′), 7.33 (1H, d, J = 2.0 Hz, H-2′), 7.10 (1H, d, J = 16.2 Hz,
H-11′ ′), 6.96 (1 , d, J = 8.3 Hz H-26′ ′), 6.90 (1H d, J = 8.2 Hz, H-5′), 6.60 (1H, d, J = 16.2 Hz, H-10′ ′),
6.43 (1H, d, J = 2.2 Hz, H-19′ ′), 6.42 (1H, d, J = 2. Hz, H-8), 6.29 (1H, d, J = 2.2 Hz, H-17′ ′), 6.28 ( H, d,
J = 2.2 Hz, H-6), 5.19 (1H, m, H-5′ ′), 3.92 (1H, m, H-4′ ′), 2.12 and 1.80 (e h 1H, overlapping signals,
H2-3′ ′), 1.84 (3H, s, H3-7′ ′), 1.78 (3H, s, H3-8′ ′), 1.55 (3H, s, H3-9′ ′); 13C-NMR (150 MHz, acetone-d6)
ppm: δ 181.6 (C-4, C-15′ ′), 165.2 (C-7, C-18′ ′), 163.9 (C-5, C-16′ ′), 159.1 (C-9), 159.0 (C-20′ ′), 155.7 (C-4′,
C-25′ ′), 154.6 (C-2), 154.3 (C-13′ ′), 136.3 (C-10′ ′), 134.0 (C-6′ ′), 130.6 (C-2′), 130.2 (C-27′ ′), 129.3 (C-6′),
128.5 (C-23′ ′), 128.3 (C-5′ ), 125.4 (C-3′), 124.8 (C-22′ ′), 124.2 (C-3), 124.0 (C-14′ ′), 123.6 (C-1′), 123.5
(C-24′ ′), 123.2 (C-11′ ′), 117.9 (C-5′), 116.5 (C-26′ ′), 106.1 (C-10, C-21′ ′), 99.9 (C-6, C-17′ ′), 94.5 (C-8,
C-19′ ′), 77.4 (C-2′ ′), 40.1 (C-3′ ′), 32.6 (C-4′ ′), 26.0 (C-8′ ′), 24.4 (C-9′ ′), 18.1 (C-7′ ′) [25]. Peaks 3, 6 and 7
were impure and the subsequent purification of these peaks was not successful despite several efforts.
No further attempt was made to identify these three PTP1B inhibitors due to the limited amount of
F. racemosa available to us.
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All isolated compounds were accessed for in vitro PTP1B inhibitory activity with RK682 as
reference compound. Compounds were dissolved in DMSO and dilution series were prepared for
IC50 determination. The dose-response curves are shown in Figure 5 and the IC50 values of all tested
compounds are given in Table 2. These results showed that mucusisoflavone B (4), an isoflavone
dimer derivative, significantly inhibited PTP1B with an IC50 value of 2.5 ± 0.2 µM, which is four
times lower than that of RK682 (10.4 ± 1.6 µM). The other isoflavonoids also displayed a strong
inhibition of PTP1B with IC50 values of 22.7 ± 1.7 µM (isoderrone, 1), 12.6 ± 1.6 µM (derrone, 2), and
21.2 ± 3.8 µM (alpinumisoflavone, 3). The comparison of compounds 1–3 showed that the PTP1B
inhibitory activity was in order of 2 > 3 ~1, suggesting that the presence of a 2,2-dimethylpyran ring
system at C-7 and C-8 produced higher inhibitory activity of compound 2. The 2,2-dimethylpyran ring
system located at C-3′ and C-4′ or at C-6 and C-7, as observed in compounds 1 or 3, might be responsible
for the decrease in inhibitory activity. Compounds 1–3 have previously been reported to possess PTP1B
inhibitory activity. While compound 1 inhibited PTP1B 78% at a concentration of 25 µM [26], IC50
of compounds 2 and 3 against PTP1B were 20.63 ± 0.17 µM and 37.52 ± 0.31 µM, respectively [27].
Thus, our results are in agreement with the previous reports. No previous investigation of the PTP1B
inhibitory activity of mucusisoflavone B (4) has been reported.
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Table 2. IC50, Ki and mode of inhibition for compounds 1–4 on PTP1B.
Compound IC50 (µM) Ki (µM) Mode of Inhibition
Isoderrone (1) 22.7 ± 1.7 21.3 ± 2.8 Non-competitive
Derrone (2) 12.6 ± .6 7.9 ± 1.9 Non-competitive
Alpinumisoflavone (3) 21.2 ± 3.8 14.3 ± 2.0 Non-competitive
Mucusisoflavone B (4) 2.5 ± 0.2 3.0 ± 0.5 Non-competitive
RK682 a 10.4 ± 1.6 n.t. n.t.
n.t.: not tested. Values are expressed as mean ± standard deviation (n = 3). a Positive control.
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2.5. Kinetics of PTP1B Inhibition
In order to examine the mode of inhibition of PTP1B by compounds 1–4, kinetic analyses were
carried out. As shown in Figure 6, all compounds inhibited in a noncompetitive manner, as increasing
the concentration of inhibitors reduced the maximum rate of the enzymatic reaction (Vmax) without
changing the binding affinity of the enzyme for the substrate (Km). During this mode of inhibition, the
substrate and the inhibitor simultaneously bind to the enzyme at different sites and the ESI complex
cannot form the product. Ki is the most important measurement for an inhibitor in noncompetitive
inhibition, as it is an indication of the affinity for an enzyme. Ki values of compounds 1–4 were
calculated to be 21.3 ± 2.8 µM, 7.9 ± 1.9 µM, 14.3 ± 2.0 µM, 3.0 ± 0.5 µM, respectively, suggesting that
compound 4 is the most tightly bound to the enzyme. Though IC50 values of compounds 1 and 3 are
comparatively equal, the Ki value of compound 3 is lower than that of compound 1, indicating that
compound 3 is a more potent inhibitor. The Ki values and mode of inhibition for compounds 1–4 are
summarized in Table 2. This is the first report on the kinetics of PTP1B inhibition of these compounds.
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3.2. Plant Material and Sample Preparation
Samples were collected from the Southern part of Vietnam in June 2014, and identified by
Son V. Dang, Curator of the VNM Herbarium, Institute of Tropical Biology, Vietnam. Voucher
specimens are stored at the General Herbarium of Vascular Plants, National History Museum,
University of Copenhagen. All the plant species, the parts used and voucher numbers are presented
in Table 1. The dried and coarsely powdered plant material (2 g) was sonicated in 20 mL MeOH
at room temperature for two hours and left overnight. The filtrate was evaporated under reduced
pressure to yield a dry residue which was then suspended in H2O (20 mL) and defatted with n-hexane
(3 × 20 mL). The hexane layer was discarded while the water layer was partitioned successively with
EtOAc (3 × 20 mL) and n-BuOH (3 × 20 mL) to produce EtOAc and n-BuOH extracts.
3.3. In Vitro PTP1B Inhibition Assay
Based on the method described by Tahtah et al. [28], the PTP1B inhibition assay was performed
at 25 ◦C using a two-component buffer, containing 50 mM Tris, 50 mM bis-Tris and 100 mM NaCl,
adjusted to pH 7.0 with acetic acid. The final reaction volume was 180 µL, including 18 µL test sample
dissolved in DMSO, 52 µL of buffer with 3.46 mM EDTA (final well concentrations 10% DMSO and
1 mM EDTA), and 60 µL of buffer with 1.5 mM pNPP and 6 mM DTT (final well concentrations 0.5 mM
pNPP and 2 mM DTT). After preincubation at 25 ◦C for 10 min, the reaction was started by addition of
50 µL of 0.001 µg/µL PTP1B stock solution (final well concentration: 0.05 µg/well). The hydrolysis
rate of pNPP to release p-nitrophenol was determined by measuring the absorbance at 405 nm every
30 s for 10 min. Preincubation and absorbance measurements were performed with a Multiscan FC
microplate photometer with a built-in incubator (Thermo Scientific, Waltham, MA, USA) coupled to
SkanIt version 2.5.1 software for data acquisition. The PTP1B inhibitory activity was expressed as
percentage inhibition and was calculated using the following formula:
% inhibition = (Slopeblank − Slopesample)/Slopeblank × 100
RK682 was used as a positive control and all measurements were performed in triplicate.
Dose-response curves and IC50 values were obtained using GraFit version 5 (Erithacus Software
Ltd., Horley, UK).
3.4. Analytical-Scale HPLC Separation
Active extracts were dissolved in methanol and filtered using a Nylon Target Syringe Filter
(0.45 µm pore size). Chromatographic separation was performed with an Agilent 1200 series instrument
(Santa Clara, CA, USA) consisting of a quaternary pump, a degasser, a thermostatted column
compartment, a photodiode-array detector, a high-performance auto sampler, and a fraction collector,
all controlled by Agilent ChemStation ver. B.03.02 software. The column used was Luna C18(2)
(Phenomenex, 150 × 4.6 µm, 3 µm particle size, 100 Å pore size) maintained at 40 ◦C. HPLC solvent A
consisted of water–acetonitrile 95:5 and solvent B consisted of acetonitrile–water 95:5, both acidified
with 0.1% formic acid. The flow rate was maintained at 0.5 mL/min with the following standard
gradient: 0 min, 0% B; 30 min, 100% B; 35 min, 100% B; 36 min, 0% B and 5 min of equilibration.
UV traces were monitored at 210, 235, 254, 280, 330 and 440 nm.
3.5. High-Resolution PTP1B Inhibition Profiling
Microfractionation of selected active extracts was performed on the same instrument, with the
same conditions as described above. For a single injection (10 µL of a 30 mg/mL extract), eluates from
1 to 30 min (EtOAc extract of P. amarus and C. fistula, n-BuOH extract of L. speciosa) and from 6 to
35 min (EtOAc extract of F. racemosa) were fractionated into 88 wells of a 96-well microplate, while
eluates from 7 to 23 min (EtOAc extract of S. cumini and E. hirta) and from 3 to 19 min (n-BuOH extract
of F. racemosa) were fractionated into 48 wells of a 96-well microplate. This leads to a resolution of 3.0
Molecules 2017, 22, 1228 9 of 12
data points per min. The following HPLC gradients were used: gradient I for separation of EtOAc
extract of P. amarus: 0 min, 0% B; 1 min, 10% B; 20 min, 35% B; 26 min, 45%; 31 min, 100% B; 36 min,
100% B; 37 min, 0% B; and 5 min of equilibration; gradient II for separation of EtOAc extract of E. hirta
and S. cumini: 0 min, 0% B; 1 min, 10% B; 20 min, 30% B; 30 min, 80% B; 31 min, 100% B; 36 min,
100% B; 37 min, 0% B; and 5 min of equilibration; standard gradient for separation of EtOAc extract of
F. racemosa: 0 min, 0% B; 30 min, 100% B; 35 min, 100% B; 36 min, 0% B; and 5 min of equilibration;
gradient III for separation of EtOAc extract of C. fistula: 0 min, 0% B; 1 min, 10% B; 30 min, 100%
B; 35 min, 100% B; 36 min, 0% B; and 5 min of equilibration; gradient IV for separation of n-BuOH
extract of L. speciosa: 0 min, 0% B; 1 min, 10% B; 20 min, 50% B; 25 min, 90% B; 30 min, 100% B; 35 min,
100% B; 36 min, 0% B; and 5 min of equilibration; gradient V for separation of n-BuOH extract of
F. racemosa: 0 min, 0% B; 1 min, 5% B; 20 min, 20% B; 30 min, 100% B; 35 min, 100% B; 36 min, 0% B;
and 5 min of equilibration. The microplates were subsequently evaporated to dryness using a Savant
SPD121P speed vacuum concentrator. The PTP1B inhibition activities for each well were determined as
described above, but replacing DMSO of test samples by DMSO for dissolution of fractionated material.
For each microplate, a positive control (RK682) as well as a negative control (blank) was included in
triplicate. High-resolution inhibition profiles were plotted by representing PTP1B inhibitory activity
against chromatographic retention time.
3.6. Preparative-Scale HPLC Separation
The preparative-scale HPLC was performed with an Agilent 1100 series instrument (Santa Clara,
CA, USA) consisting of a quaternary pump, a degasser, a thermostated column compartment,
a photodiode-array detector, a high-performance auto sampler, and a fraction collector, all controlled
by Agilent ChemStation ver. B.01.01 software and equipped with a reversed-phase Luna C18(2) column
(Phenomenex, 250 × 21.2 mm, 5 µm, 100 Å). The column was operated at room temperature, the flow
rate was maintained at 20 mL/min, using a binary mixture of water–acetonitrile (95:5 v/v) as eluent A
and acetonitrile–water (95:5 v/v) as eluent B, both acidified with 0.1% formic acid. A volume of 900 µL
50 mg/mL extract was injected and the following gradients were used: standard gradient to obtain
Fr.1: 0 min, 0% B; 30 min, 100% B; 35 min, 100% B; 36 min, 0% B and 5 min of equilibration; gradient VI
to isolate active compounds of F. racemosa EtOAc extract: 0 min, 40% B; 50 min, 75% B; 51 min, 100% B;
56 min, 100% B; 57 min, 40% B; and 5 min of equilibration.
3.7. HPLC-HRMS-SPE-NMR Analysis
HPLC-HRMS-SPE-NMR analysis was performed on a platform consisting of an Agilent 1260
chromatograph (Santa Clara, CA, USA), a Bruker micrOTOF-Q II mass spectrometer (Bruker Daltonik,
Bremen, Germany), a Knauer Smartline 120 pump (Knauer, Berlin, Germany), a Prospekt-2 SPE unit
(Spark Holland, Emmen, The Netherlands), a Gilson 215 liquid handler (Gilson, Middleton, WI,
USA), and a Bruker Avance III 600 MHz NMR spectrometer. Agilent 1260 system consists of an auto
sampler, a quaternary pump with integrated degasser, a thermostatted column compartment, and a
photodiode-array detector. Separation was performed with column, temperature, solvent composition
and flow rate as described above, using the following elution profile (gradient VI): 0 min, 40% B;
50 min, 75% B; 51 min, 100% B; 56 min, 100% B; 57 min, 40% B; and 5 min of equilibration. The
column eluate was connected to a T-piece splitter to direct 1% of the flow to a micrOTOF-Q II mass
spectrometer, equipped with an electrospray ionization (ESI) interface. Mass spectra were acquired
in positive ion mode, using drying temperature of 200 ◦C, capillary voltage of 4100 V, nebulizer
pressure of 2.0 bar, and drying gas flow of 7 L/min. The rest of the HPLC eluate (99%) was directed
to the photo-diode array (PDA) detector and subsequently diluted with 1.0 mL/min of water by a
Knauer Smartline 120 pump, prior to trapping on 10 × 2 mm i.d. Resin GP (general purpose, 5–15 µm,
spherical shape, polydivinyl-benzene solid phase) SPE cartridges from Spark Holland. Before trapping,
the cartridges were preconditioned with 500 µL of acetonitrile and subsequently equilibrated with
500 µL of water. Selected peaks were trapped cumulatively after 10 consecutive separations using
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UV absorption-thresholds to trigger trapping. The loaded SPE cartridges were dried with a stream of
nitrogen gas for 45 min, and subsequently eluted with 30 µL deuterated acetonitrile-d3 into 1.7 mm
NMR tubes (Bruker Biospin, Germany) using a Gilson 215 liquid handler. The tubes were filled
with 30 µL of eluted sample and sealed with plastic balls. HPLC separations, mass spectrometric
measurements, and analyte trapping on SPE cartridges were controlled using Hystar ver. 3.2 software
(Bruker Daltonik, Bremen, Germany), whereas cartridge elution was controlled by Prep Gilson ST
ver. 1.2 software (Bruker Biospin, Karlsruhe, Germany).
3.8. NMR Experiments
All NMR spectra were recorded at 300 K either in acetonitrile-d3 (for material analyzed in
the HPLC-HRMS-SPE-NMR mode) or in acetone-d6 (for material isolated on preparative scale).
NMR experiments were performed using either a Bruker Avance III 600 MHz NMR spectrometer
(1H operating frequency 600.13 MHz) equipped with a Bruker SampleJet sample changer and a
cryogenically cooled gradient inverse triple-resonance 1.7 mm TCI probe-head (Bruker Biospin,
Rheinstetten, Germany) or a 600 MHz Bruker Avance III HD spectrometer equipped with a
cryogenically cooled 5 mm DCH probe optimized for 13C and 1H observation. Bruker standard
pulse sequences were used throughout this study. Icon NMR version 4.2 (Bruker Biospin) was used for
controlling automated acquisition of NMR data (temperature equilibration to 300 K, optimization of
lock parameters, gradient shimming, and setting of receiver gain). One-dimensional 1H- and 13C-NMR
spectra were acquired with 30◦-pulses, 3.66 s inter-pulse intervals and 64k data points. NMR data
acquisition and processing was performed using Topspin version 3.5 (Bruker Biospin).
3.9. Kinetics of PTP1B Inhibition
Enzyme kinetics of isolated PTP1B inhibitors was measured in triplicate using the standard
assay conditions described above. Reactions were carried out with increasing concentrations of
pNPP (0.125, 0.25, 0.5, 1.0, 2.0 and 4.0 mM) as substrate in the absence and presence of test samples
(4 concentrations). The mode of inhibition was determined graphically from the Lineweaver-Burk
plots. Kinetic parameters were calculated by fitting the data to the Michaelis–Menten equation using
non-linear regression analysis (GraphPad Prism 7.0, GraphPad Software Inc., La Jolla, CA, USA).
4. Conclusions
In conclusion, PTP1B inhibitory activity of 40 extracts from 18 Vietnamese medicinal plants was
measured in vitro. Our study showed that 21 extracts significantly suppressed PTP1B enzyme. The
study also demonstrated that F. racemosa can be used as a natural source of PTP1B inhibitors. From this
plant, PTP1B inhibitory activity has already been reported for three known compounds and PTP1B
inhibitory activity has been reported for the first time for one known compound. This is also the first
report on the kinetics of PTP1B inhibition of these compounds. The use of the high-resolution PTP1B
inhibition profile combined with HPLC-HRMS-SPE-NMR has proved to be a valuable targeting tool
for analysis of a crude plant extract.
Supplementary Materials: Supplementary material are available online.
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